



## ***Publication of a Shareholders Letter***

**Paris (France), Copenhagen (Denmark), January 28, 2015** – Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of a Shareholders Letter <sup>(1)</sup>.

For this new year, Onxeo publishes a Shareholders Letter to update on major achievements of 2014 and discuss outlooks for the coming months.

*(1) The Shareholders Letter is available on the website at: [www.onxeo.com](http://www.onxeo.com) (News or Investors).*

### **About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

### ***Key products at advanced development stage are:***

Livataq® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

*For more information, visit the website [www.onxeo.com](http://www.onxeo.com)*

### ***Disclaimer***

*This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on the company’s website ([www.onxeo.com](http://www.onxeo.com)).*

### **Contacts :**

Judith Greciet, CEO  
[j.greciet@onxeo.com](mailto:j.greciet@onxeo.com)  
Nicolas Fellmann, CFO  
[n.fellmann@onxeo.com](mailto:n.fellmann@onxeo.com)  
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP  
[caroline@alizerp.com](mailto:caroline@alizerp.com) / [scolin@alizerp.com](mailto:scolin@alizerp.com)  
+33 6 64 18 99 59 / +33 1 44 54 36 62